研究的主要终点为盲法独立中央审查(BICR)评估的HR+/HER2低表达人群的PFS,关键次要终点为BICR评估的意向治疗(ITT,包括HER2低表达、HER2超低表达)人群的PFS,HER2低表达和ITT人群的OS;其他次要终点包括研究者评估(INV)的HER2低表达人群的PFS,经BICR和INV评估的HER2低表达和ITT人群的DoR和ORR,安全性及耐受性。 图2. ...
然而,近年来,有一批HER2表达水平低(HER2-low)的乳腺癌患者引起了研究者的关注。这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 ...
e13030#Background:IHC/FISH is currently the gold standard method of HER2 expression assessment on breast cancer (BC) cells. Recent studies regarding HER2-low category show that the semi-quantitative methods are inaccurate. False-negative results may have a negative impact on the prognosis and ...
目前,HER2 低表 达乳腺癌的生物学特征尚不十分明确,HER2 低表达与 HER2 零表达患者预后以及传统治疗 反应差异亦不明确。该研究旨在明确 HER2 低表达与 HER2 零表达早期乳腺癌(eBC)患者 新辅助化疗(NAC)后的化疗敏感性和长期预后。 研...
ER positive, HER2 negative Breast Cancer - Pipeline Insight, 2024 Drug Pipelines 40 Pages April 2024 Global From €985 €1232 Breast Cancer Pipeline Analysis Report Report 150 Pages August 2024 Global From €2462 Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (Her2- Breast Cancer)...
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and repo...
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
[13]Aditya Bardia, et al. Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01. 2023 SABCS Abstract GS02-01. ...
Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;852748.Lin M, et al. Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer....
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...